Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Shifts Early R&D Focus With iPierian Purchase

This article was originally published in The Pink Sheet Daily

Executive Summary

The big pharma adds a neurodegenerative asset to its early stage pipeline with the $175 million acquisition of iPierian; the firm will begin with studying the drug in a rare genetic disorder.


Related Content

AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
iZumi & Pierian Join Forces to Advance EMerging iPS Cell Platform


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts